Can a Patient's own immune cells be trained to fight advanced GI cancers?
NCT ID NCT07735065
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This early trial is testing an experimental cell therapy called cCTL-GL01 in people with advanced stomach, esophageal, colon, or rectal cancers that have not responded to standard treatments. The therapy uses a patient's own immune cells, which are specially trained in the lab to recognize and attack their tumor. The main goals are to check the safety of the treatment and to see whether it can shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a personalized cell therapy made from the patient's own immune cells, called cCTL-GL01
- What this could lead to
- If it works, this approach could offer a new treatment option for people with advanced gastrointestinal cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early, small trial focused on safety, so it is not yet known whether the therapy will effectively shrink tumors. Potential side effects include serious immune reactions such as cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.